Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Biochemical Pharmacology

• Publication date

  2003-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/S0006-2952(03)00559-8PMID 14609731
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins Published, JLR Papers in Press, March 1, 2003. DOI 10.1194/jlr.M200452-JLR200

  2003cited by this paper
• Altered distribution of platelet-activating factor- acetylhydrolase activity between LDL and HDL as a function of the severity of hypercholesterolemia.

  2002cited by this paper
• Inflammation, bioactive lipids and atherosclerosis: potential roles of a lipoprotein-associated phospholipase A2, platelet activating factor-acetylhydrolase.

  2002cited by this paper
• Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB

  2002cited by this paper
• Peroxisome proliferator-activated receptor-α activation and high-density lipoprotein metabolism☆

  2001cited by this paper
• Adenovirus-Mediated Gene Transfer of Human Platelet-Activating Factor–Acetylhydrolase Prevents Injury-Induced Neointima Formation and Reduces Spontaneous Atherosclerosis in Apolipoprotein E–Deficient Mice

  2001cited by this paper
• A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.

  2001cited by this paper
• PPARS, metabolic disease and atherosclerosis.

  2001cited by this paper
• Peroxisome proliferator-activated receptor-alpha activation and high-density lipoprotein metabolism.

  2001cited by this paper
• Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group.

  2000cited by this paper
• HDLassociated PAF‐AH reduces endothelial adhesiveness in apoE−/− mice

  2000cited by this paper
• Cellular source(s) of platelet-activating-factor acetylhydrolase activity in plasma.

  1999cited by this paper
• Apolipoprotein B-100 conformation and particle surface charge in human LDL subspecies: implication for LDL receptor interaction.

  1998cited by this paper
• Identification of the G994--> T missense in exon 9 of the plasma platelet-activating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men.

  1998cited by this paper
• Determinants of plasma platelet-activating factor acetylhydrolase: heritability and relationship to plasma lipoproteins.

  1997cited by this paper
• Increased activity of platelet‐activating factor acetylhydrolase in low‐density lipoprotein subfractions induces enhanced lysophosphatidylcholine production during oxidation in patients with heterozygous familial hypercholesterolaemia

  1997cited by this paper
• PAF-acetylhydrolase activity of Lp(a) before and during Cu(2+)-induced oxidative modification in vitro.

  1996cited by this paper
• PAF-degrading acetylhydrolase is preferentially associated with dense LDL and VHDL-1 in human plasma. Catalytic characteristics and relation to the monocyte-derived enzyme.

  1995cited by this paper
• Enhanced Association of Platelet-activating Factor Acetylhydrolase with Lipoprotein (a) in Comparison with Low Density Lipoprotein (*)

  1995cited by this paper
• Human macrophages secret platelet-activating factor acetylhydrolase.

  1990cited by this paper
• Lipoproteins alter the catalytic behavior of the platelet-activating factor acetylhydrolase in human plasma.

  1989cited by this paper
• The degradation of platelet-activating factor in the plasma of a patient with familial high density lipoprotein deficiency (Tangier disease).

  1985cited by this paper
• Receptor-mediated control of cholesterol metabolism.

  1976cited by this paper

• Mechanism of Oxidized Phospholipid-related Inflammatory Response in Vascular Ageing.

  2023cites this paper
• Mast Cells and Basophils in IgE-Independent Anaphylaxis

  2023cites this paper
• α-Hederin inhibits the platelet activating factor-induced metastasis of HCC cells through disruption of PAF/PTAFR axis cascaded STAT3/MMP-2 expression.

  2022cites this paper
• Low acylation stimulating protein levels are associated with cardiometabolic disorders–secondary to autoimmune activation?

  2016cites this paper
• Recommendations for severe hypertriglyceridemia treatment, are there new strategies?

  2014cites this paper
• Relationship between platelet activating factor acetylhydrolase activity and apolipoprotein B levels in patients with peanut allergy

  2014cites this paper
• Pathophysiological role and clinical significance of lipoprotein-associated phospholipase A₂ (Lp-PLA₂) bound to LDL and HDL.

  2014cites this paper
• Biological Activities of Proteins and Marine‐derived Peptides from Byproducts and Seaweeds

  2013cites this paper
• Inflammatory biomarkers and cardiovascular risk assessment. Current knowledge and future perspectives.

  2013cites this paper
• Differential genomic changes caused by cholesterol- and PUFA-rich diets in regenerated porcine coronary endothelial cells.

  2012cites this paper
• In Vitro and In Vivo Effects of Statins on Platelet-Activating Factor and Its Metabolism

  2011cites this paper
• Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia

  2011cites this paper
• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2 ): a review

  2011cites this paper
• Therapeutic modulation of lipoprotein-associated phospholipase A2 (Lp-PLA2).

  2011cites this paper
• Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.

  2009cites this paper
• Altered distribution of plasma platelet-activating factor acetylhydrolase between high-density lipoprotein and low-density lipoprotein in patients with polycystic ovary syndrome.

  2009cites this paper
• The role of lipoprotein-associated phospholipase A2 in atherosclerosis may depend on its lipoprotein carrier in plasma.

  2009cites this paper
• Dose-dependent Effect of Rosuvastatin Treatment on HDL-subfraction Phenotype in Patients With Primary Hyperlipidemia

  2009cites this paper
• Lipoprotein-associated phospholipase A2 mass is significantly reduced in dyslipidemic patients treated with lifestyle modification and combination lipid-modifying drug therapy.

  2009cites this paper
• Effects of orlistat, alone or combined with hypolipidemic drugs, on cardiovascular risk factors

  2009cites this paper
• Alterations in the High Density Lipoprotein Phenotype and HDL-Associated Enzymes in Subjects with Metabolic Syndrome

  2008cites this paper
• Lipoprotein-Associated Phospholipase A2 Predicts Progression of Cardiac Allograft Vasculopathy and Increased Risk of Cardiovascular Events in Heart Transplant Patients

  2008cites this paper
• The effects of ezetimibe and orlistat, alone or in combination, on high-density lipoprotein (HDL) subclasses and HDL-associated enzyme activities in overweight and obese patients with hyperlipidaemia

  2008cites this paper
• Identification of a Domain That Mediates Association of Platelet-activating Factor Acetylhydrolase with High Density Lipoprotein*

  2008cites this paper
• Lysophosphatidylcholine contents in plasma LDL in patients with type 2 diabetes mellitus: relation with lipoprotein-associated phospholipase A2 and effects of simvastatin treatment.

  2008cites this paper
• Platelet activating factor-acetylhydrolase (PAF-AH) activity and HDL levels, but not PAF-AH gene polymorphisms, are associated with successful aging in Sicilian octogenarians

  2008cites this paper
• In vivo markers of oxidative stress and therapeutic interventions.

  2008cites this paper
• Isoprostanes and Phospholipases, Markers and Mediators of Oxidative Stress

  2007cites this paper
• Differential Effect of Hypolipidemic Drugs on Lipoprotein-Associated Phospholipase A2

  2007cites this paper
• Role of Inflammation in Atherosclerosis*

  2007cites this paper
• Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

  2007cites this paper
• Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.

  2007cites this paper
• Clinical importance and therapeutic modulation of small dense low-density lipoprotein particles

  2007cites this paper
• Institute of Experimental and Clinical Pharmacology and Toxicology Clinical Pharmacology

  2007cites this paper
• Markers and Mediators of Oxidative Stress

  2007cites this paper
• C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients.

  2006cites this paper
• Effect of Barnidipine on Blood Pressure and Serum Metabolic Parameters in Patients With Essential Hypertension: A Pilot Study

  2006cites this paper
• Clinical aspects of plasma platelet-activating factor-acetylhydrolase.

  2006cites this paper
• Regulating inflammation through the anti-inflammatory enzyme platelet-activating factor-acetylhydrolase.

  2005cites this paper
• Genetics and molecular biology.

  2005cites this paper
• Intravascular adenovirus-mediated lipoprotein-associated phospholipase A2 gene transfer reduces neointima formation in balloon-denuded rabbit aorta.

  2005cites this paper
• Lipoprotein-associated PAF-acetylhydrolase activity in subjects with the metabolic syndrome.

  2005cites this paper
• A review of the lipid-related effects of fluvastatin

  2005cites this paper
• Lipoprotein-associated phospholipase A2 as a biomarker for coronary disease and stroke

  2005cites this paper
• Lack of Association Between Carotid Intima-Media Thickness and PAF-Acetylhydrolase Mass and Activity in Patients with Primary Hyperlipidemia

  2005cites this paper
• HDL and inflammation in atherosclerosis.

  2004cites this paper
• Platelet-activating factor acetylhydrolase is not associated with carotid intima-media thickness in hypercholesterolemic Sicilian individuals.

  2004cites this paper
• Alterations of Paraoxonase and Platelet-Activating Factor Acetylhydrolase Activities in Patients on Peritoneal Dialysis

  2004cites this paper
• Effects of Antihypertensive and Hypolipidemic Drugs on Plasma and High-Density Lipoprotein-Associated Platelet Activating Factor-Acetylhydrolase Activity

  2004cites this paper